Hyperfine (HYPR) Liabilities and Shareholders Equity (2020 - 2026)
Hyperfine (HYPR) posted Liabilities and Shareholders Equity of $60.3 million for Q1 2026, up 9.19% on a QoQ basis from $55.3 million in Q4 2025, and up 13.04% year-over-year from $53.4 million in Q1 2025.
Hyperfine (HYPR) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Hyperfine's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $60.3 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 13.04% year-over-year to $60.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $202.3 million (down 21.65% YoY) and the FY2025 annual result came in at $55.3 million, down 6.18% from the prior year.
- Liabilities and Shareholders Equity was $60.3 million for Q1 2026 at Hyperfine, up from $55.3 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $178.8 million in Q1 2022 and bottomed at $41.5 million in Q3 2025.
- A 5-year average of $94.2 million and a median of $85.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity plunged 40.96% — and 2026, when it advanced 13.04%.
- Hyperfine's Liabilities and Shareholders Equity stood at $134.1 million in 2022, then slipped by 29.73% to $94.2 million in 2023, then tumbled by 37.47% to $58.9 million in 2024, then dropped by 6.18% to $55.3 million in 2025, then increased by 9.19% to $60.3 million in 2026.
- Business Quant data shows HYPR's Liabilities and Shareholders Equity at $60.3 million in Q1 2026, $55.3 million in Q4 2025, and $41.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | Hyperfine | 92.81 Mn | 51.53 Mn | 1.98 Mn | 60.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.34 Mn |
| Dec 31, 2025 | 55.26 Mn |
| Sep 30, 2025 | 41.51 Mn |
| Jun 30, 2025 | 45.23 Mn |
| Mar 31, 2025 | 53.38 Mn |
| Dec 31, 2024 | 58.90 Mn |
| Sep 30, 2024 | 69.39 Mn |
| Jun 30, 2024 | 76.61 Mn |
| Mar 31, 2024 | 85.44 Mn |
| Dec 31, 2023 | 94.20 Mn |
| Sep 30, 2023 | 103.06 Mn |
| Jun 30, 2023 | 112.61 Mn |
| Mar 31, 2023 | 122.10 Mn |
| Dec 31, 2022 | 134.05 Mn |
| Sep 30, 2022 | 148.33 Mn |
| Jun 30, 2022 | 161.71 Mn |
| Mar 31, 2022 | 178.83 Mn |
| Dec 31, 2021 | 202.47 Mn |
| Sep 30, 2021 | 207.94 Mn |
| Jun 30, 2021 | 208.25 Mn |